JPH02255607A - Whitening cosmetic - Google Patents
Whitening cosmeticInfo
- Publication number
- JPH02255607A JPH02255607A JP7947189A JP7947189A JPH02255607A JP H02255607 A JPH02255607 A JP H02255607A JP 7947189 A JP7947189 A JP 7947189A JP 7947189 A JP7947189 A JP 7947189A JP H02255607 A JPH02255607 A JP H02255607A
- Authority
- JP
- Japan
- Prior art keywords
- whitening
- caffeic acid
- skin
- formula
- whitening cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 20
- 230000002087 whitening effect Effects 0.000 title claims abstract description 19
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical class OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims abstract description 29
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims abstract description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 3
- 206010042496 Sunburn Diseases 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract description 2
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000000485 pigmenting effect Effects 0.000 abstract 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 11
- 229940074360 caffeic acid Drugs 0.000 description 11
- 235000004883 caffeic acid Nutrition 0.000 description 11
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical class OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 4
- 230000008099 melanin synthesis Effects 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010040829 Skin discolouration Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- AFDXODALSZRGIH-QPJJXVBHSA-N (E)-3-(4-methoxyphenyl)prop-2-enoic acid Chemical compound COC1=CC=C(\C=C\C(O)=O)C=C1 AFDXODALSZRGIH-QPJJXVBHSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000872198 Serjania polyphylla Species 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、色白化粧料、さらに詳しくは、美白や日焼は
防止を目的として皮膚に使用される色白化粧料に関する
。DETAILED DESCRIPTION OF THE INVENTION (Industrial Application Field) The present invention relates to a skin-lightening cosmetic, and more particularly to a skin-lightening cosmetic that is used for skin whitening and prevention of sunburn.
（従来の技術）
一般に、皮膚のしみ、そばかす等の発生は、ホルモンの
異常や紫外線の刺激に起因するメラニン色素の異常沈着
が原因と考えられている。そして、このしみ、そばかす
等の治療にはたとえばビタミンＣ，グルタチオン、シス
ティン、さらにはコウジ酸系化合物等のメラニンの生成
を抑制するチロシナーゼ活性阻害剤やハイドロキノン製
剤が使用されている。(Prior Art) It is generally believed that the appearance of spots, freckles, etc. on the skin is caused by abnormal deposition of melanin pigment caused by hormonal abnormalities or stimulation by ultraviolet rays. For the treatment of spots, freckles, etc., tyrosinase activity inhibitors and hydroquinone preparations, such as vitamin C, glutathione, cysteine, and even kojic acid compounds, which inhibit melanin production, are used.
（発明が解決しようとする問題点）
しかしながら、上述のような従来のチロシナーゼ活性阻
害剤等は、いずれもそれぞれ次のような問題点を有して
いた。(Problems to be Solved by the Invention) However, all of the conventional tyrosinase activity inhibitors as described above have the following problems.
（イ）先ず、ビタミンＣは、安定性の面で問題があり、
特に水分を含む系では不安定で変色、変臭し易く、従っ
て化粧料の有効成分としての使用が必ずしも容易ではな
かった。(b) First, vitamin C has problems in terms of stability.
Particularly in a system containing water, it is unstable and tends to change color and odor, so it has not always been easy to use it as an active ingredient in cosmetics.
（ロ）又、グルタチオンやシスティン等のチオール系の
化合物は、特異な臭気があり且つ酸化され易いため、化
粧料への配合は避けられている。(b) Furthermore, thiol-based compounds such as glutathione and cysteine have a unique odor and are easily oxidized, so their inclusion in cosmetics is avoided.
（ハ）しかも、上記ビタミンＣやグルタチオン。(c) Moreover, the above-mentioned vitamin C and glutathione.
システィンは、美白効果の発現が非常に緩慢でその美白
効果は十分ではなかった。Cysteine had a very slow whitening effect, and its whitening effect was not sufficient.
（ニ）さらに、コウジ酸系化合物等は、上記各物質に比
べると美白効果の点で幾分優れてはいるが、このコウジ
酸系化合物をもってしても、その美白効果は、化粧料中
の有効成分としては未だ満足できるものではなく、しか
も、安全性等すべての条件を具備したものは未だ開発さ
れていなかった。(iv) Furthermore, although kojic acid compounds are somewhat superior to the above-mentioned substances in terms of whitening effect, even with these kojic acid compounds, the whitening effect is not as good as that in cosmetics. It is still unsatisfactory as an active ingredient, and furthermore, one that satisfies all requirements such as safety has not yet been developed.
（ホ）さらに、ハイドロキノン製剤は、上記従来のもの
の中では最も美白効果は優れているが、逆に強い皮膚感
作性を有するため、一般には使用は制限されている。(e) Furthermore, hydroquinone preparations have the best whitening effect among the above conventional preparations, but on the other hand, they have strong skin sensitization properties, so their use is generally limited.
本発明は、以上のような問題点をすべて解決するために
なされたもので、非常に優れた美白効果を有する色白化
粧料を提供することを目的とする。The present invention was made to solve all of the above-mentioned problems, and an object of the present invention is to provide a skin-whitening cosmetic that has an extremely excellent whitening effect.
（問題点を解決するための手段）
本発明は、従来の色白化粧料が、いずれも美白効果の向
上を抜本的に図るものではない点に鑑み、主としてメラ
ニン抑制阻止効果の観点からこの問題を解決せんとして
なされたもので、その問題点を解決するための手段は、
次の一般式〔Ｉ］〔式中、Ｒ１は、−０Ｒ２又は−Ｎ（
Ｒ２）２で示され、さらにＲ２は、炭素数１〜２６の飽
和若しくは不飽和の鎖式炭化水素基、２−ヒドロキシエ
チル基、又は水素原子を示す。ｎは２又は３の整数を示
す。(Means for Solving the Problems) In view of the fact that none of the conventional skin-lightening cosmetics fundamentally aims to improve the whitening effect, the present invention solves this problem mainly from the viewpoint of the melanin suppression effect. This was done as a solution, and the means to solve the problem are:
The following general formula [I] [wherein R1 is -0R2 or -N(
R2)2 represents a saturated or unsaturated chain hydrocarbon group having 1 to 26 carbon atoms, a 2-hydroxyethyl group, or a hydrogen atom. n represents an integer of 2 or 3.
〕で示されるカフェイン酸誘導体を配合してなることに
ある。It is made by blending the caffeic acid derivative shown in ].
（作用）
すなわち、上記のような化粧料中に配合されたカフェイ
ン酸誘導体がメラニン生成抑制作用を有するため、これ
を配合した化粧料は、皮膚の黒化や色素沈着等の優れた
防止効果を有するのである。(Effect) In other words, since the caffeic acid derivatives blended into cosmetics as mentioned above have the effect of inhibiting melanin production, cosmetics blended with this have an excellent preventive effect on skin darkening and pigmentation. It has.
（実施例） 以下、本発明の実施例について説明する。(Example) Examples of the present invention will be described below.
実施例１
本実施例は、次式で示されるカフェイン酸を配合した化
粧料についての実施例である。Example 1 This example is about a cosmetic containing caffeic acid represented by the following formula.
その配合のための処方例は次のとおりである。A prescription example for its formulation is as follows.
（成分） （重量％）ステアリンＲ
１０，０
ステアリルアルコール ４．０ステアリン酸ブ
チル ８．０モノステアリン酸グリセリン
２．０カフエイン酸 ２．０
プロピレングリコール １０．０グリセリン
４．０
水酸化カリウム
香料及び防腐剤
精製水
０．４
微量
残量
合計
１００、０
実施例２
本実施例は上記実施例１と同様にカフェイン酸を配合し
たものであるが、その配合の処方例は実施例１と異なる
。(Ingredients) (Weight%) Stearin R
10.0 Stearyl alcohol 4.0 Butyl stearate 8.0 Glyceryl monostearate
2.0 Caffeic acid 2.0 Propylene glycol 10.0 Glycerin
4.0 Potassium hydroxide fragrance and preservative Purified water 0.4 Total trace amount remaining 100.0 Example 2 This example contains caffeic acid in the same manner as in Example 1 above, but with the addition of caffeic acid. The prescription example is different from Example 1.
その処方例は次のとおりである。An example of its prescription is as follows.
（成分） （重量％）ステアリン酸
５．０ミツロウ
１．０ラノリン ０．５モ
ノステアリン酸グリセリン ０．５２−エチルヘキサ
ン酸セチル ７．０ミリスチン酸オクチルドデシル
３．０セスキオレイン酸ソルビタン １．（＋パラメ
トキシケイヒ酸−２−
エチルヘキシル ４．０
２−ハイドロキシ−４−メトキ
シベンゾフェノン １．０
カフエイン酸 ２．０
プロピレングリコール ２．０トリエタノール
アミン ０．６カルボキシビニルボリマー
０．２香料及び防腐剤 微量
精製水 残量
合計 １００．０試験例
上記実施例のような化粧料の配合成分であるカフェイン
酸のメラニン抑制効果について次のような試験を行った
。(Ingredients) (Weight%) Stearic acid 5.0 Beeswax
1.0 Lanolin 0.5 Glycerin monostearate 0.5 Cetyl 2-ethylhexanoate 7.0 Octyldodecyl myristate
3.0 Sorbitan Sesquioleate 1. (+2-ethylhexyl para-methoxycinnamate 4.0 2-hydroxy-4-methoxybenzophenone 1.0 caffeic acid 2.0 Propylene glycol 2.0 Triethanolamine 0.6 Carboxyvinyl polymer
0.2 Fragrance and preservative Trace amount of purified water Total remaining amount 100.0 Test Example The following test was conducted on the melanin suppressing effect of caffeic acid, which is a component of the cosmetics as in the above example.
（１）使用細胞
細胞としてマウスメラノーマ８１６Ｃ２Ｍ細胞を使用し
た。(1) Cells used Mouse melanoma 816C2M cells were used.
（２）培養条件
イーグルＭＥＭ培地に１０％ＦＢＳを添加した培地を用
いた。Ｂ１６細胞を植え込み、３７℃、５％ＣＯ７に設
定したＣＯ２培養器で２日間培養し、その後、所定の濃
度のカフェイン酸又はコウジ酸を添加し、さらに４日間
培養した。(2) Culture conditions Eagle MEM medium supplemented with 10% FBS was used. B16 cells were implanted and cultured for 2 days in a CO2 incubator set at 37°C and 5% CO7, and then caffeic acid or kojic acid at a predetermined concentration was added and cultured for an additional 4 days.
（３）メラニン生成阻止力の判定
植え込んでから６日間培養した後、増殖した細胞をトリ
プシンで分散後、１１０００ｒｐ Ｘ１０ｍ１ｎで遠心
分離して集め、その白色化度を肉眼的に判定した。(3) Determination of ability to inhibit melanin production After culturing for 6 days after implantation, the proliferated cells were dispersed with trypsin and collected by centrifugation at 11000 rpm x 10 m1, and the degree of whitening was visually determined.
（４）判定結果 判定結果は数表のとおりである。(4) Judgment results The judgment results are shown in the numerical table.
上記表において、−や十等は次のような意味を表す。In the above table, - and tens etc. represent the following meanings.
：黒色で白色化は認められない。: Black with no whitening observed.
十：無添加に比べ僅かに白色化が認められる。10: Slight whitening is observed compared to the sample without additives.
＋十：無添加に比べ明らかに白色化を示す。+10: Clearly shows whitening compared to no additive.
十干＋：白〜灰色で黒色と認められない。Juboshi+: white to gray and not recognized as black.
以上の結果より、上記実施例の有効成分であるカフェイ
ン酸は顕著なメラニン生成阻止効果を表すものである。From the above results, caffeic acid, which is the active ingredient in the above examples, exhibits a remarkable melanin production inhibiting effect.
又、細胞毒性も認められなかった。Moreover, no cytotoxicity was observed.
尚、上記実施例では、化粧料に配合される有効成分とし
てカフェイン酸を使用したが、このカフェイン酸に限ら
ず、要は上記［Ｉ］式で示されるカフェイン酸の誘導体
であれば、本発明の化粧料に配合される有効成分として
使用可能である。In the above example, caffeic acid was used as an active ingredient blended into the cosmetic, but it is not limited to this caffeic acid, and any derivative of caffeic acid represented by the above formula [I] may be used. , can be used as an active ingredient in the cosmetic composition of the present invention.
又、化粧料の基剤も上記実施例に限定されるものではな
く、クリーム、ローション等の基剤の種類に応じて任意
のものを適宜変更して使用することが可能である。Further, the base of the cosmetic is not limited to the above examples, and any base can be used with appropriate changes depending on the type of base of cream, lotion, etc.
（発明の効果）
取上のように、本発明は、化粧料中に、上記のような優
れたメラニン抑制作用を有するカフェイン酸誘導体を配
合したものなるため、そのメラニン生成抑制作用により
、皮膚の黒化や色素沈着を防止できる等、非常に優れた
美白効果が得られるという顕著な効果を有するに至った
。(Effects of the Invention) As mentioned above, the present invention is a cosmetic containing a caffeic acid derivative having an excellent melanin-inhibiting effect as described above. It has come to have remarkable effects, such as being able to prevent darkening and pigmentation, and provide extremely excellent whitening effects.
又、皮膚に対する刺激等も特に認められなかった。Moreover, no particular irritation to the skin was observed.
【図面の簡単な説明】
図面は、一実施例としての化粧料の配合成分であるカフ
ェイン酸の紫外線吸収スペクトルを示すチャート図であ
る。BRIEF DESCRIPTION OF THE DRAWINGS The drawing is a chart showing the ultraviolet absorption spectrum of caffeic acid, which is a component of a cosmetic as an example.
Claims (1)
で示され、さらにＲ＿２は、炭素数１〜２６の飽和若し
くは不飽和の鎖式炭化水素基、２−ヒドロキシエチル基
、又は水素原子を示す。ｎは２又は３の整数を示す。 〕で示されるカフェイン酸誘導体を配合してなることを
特徴とする色白化粧料。[Claims] General formula ▲ Numerical formula, chemical formula, table, etc. ▼ [In the formula, R_1 is -OR_2 or -N(R_2)_2
Further, R_2 represents a saturated or unsaturated chain hydrocarbon group having 1 to 26 carbon atoms, a 2-hydroxyethyl group, or a hydrogen atom. n represents an integer of 2 or 3. A whitening cosmetic characterized by containing a caffeic acid derivative shown in ].
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7947189A JPH02255607A (en) | 1989-03-29 | 1989-03-29 | Whitening cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7947189A JPH02255607A (en) | 1989-03-29 | 1989-03-29 | Whitening cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02255607A true JPH02255607A (en) | 1990-10-16 |
Family
ID=13690801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7947189A Pending JPH02255607A (en) | 1989-03-29 | 1989-03-29 | Whitening cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02255607A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1003833A3 (en) * | 1989-10-20 | 1992-06-23 | Oreal | PHARMACEUTICAL AND COSMETICS depigmentation BASED caffeic acid |
| JP2003267857A (en) * | 2002-01-11 | 2003-09-25 | Mitsui Chemicals Inc | Skin care preparation and composition of skin care preparation |
| KR20140124987A (en) * | 2013-04-17 | 2014-10-28 | 충북대학교 산학협력단 | Skin Whitening Composition Comprising Caffeic Acid Derivatives as the Active Ingredients |
-
1989
- 1989-03-29 JP JP7947189A patent/JPH02255607A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1003833A3 (en) * | 1989-10-20 | 1992-06-23 | Oreal | PHARMACEUTICAL AND COSMETICS depigmentation BASED caffeic acid |
| JP2003267857A (en) * | 2002-01-11 | 2003-09-25 | Mitsui Chemicals Inc | Skin care preparation and composition of skin care preparation |
| KR20140124987A (en) * | 2013-04-17 | 2014-10-28 | 충북대학교 산학협력단 | Skin Whitening Composition Comprising Caffeic Acid Derivatives as the Active Ingredients |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2502318B2 (en) | Whitening cosmetics | |
| KR100855457B1 (en) | Composition for skin whitening comprising arctiin, arctigenin or compound thereof as active ingredient | |
| BR112015021033B1 (en) | COSMETIC COMPOSITION, NON-THERAPEUTIC METHODS TO REDUCE OR TREAT SKIN AGING SIGNS AND TO PREVENT, LIGHTEN OR REDUCE THE APPEARANCE OF VISIBLE SKIN DISCONTINUITIES AND USES OF A COMPOSITION | |
| JP2000095663A (en) | Agent for external use containing plant extract | |
| KR20010057585A (en) | External preparation for skin | |
| WO2010053340A2 (en) | Skin-whitening composition | |
| KR20010015219A (en) | Topical Cosmetic Compositions Comprising Benzaldoximes | |
| KR101919616B1 (en) | skin whitening agent | |
| KR100521768B1 (en) | Cosmetic Compositions for a Skin Whitening | |
| WO2014092166A1 (en) | Tyrosinase activity inhibitor and whitening agent | |
| JPH1072330A (en) | Tyrosinase activity inhibitor and cosmetic | |
| JPH02255607A (en) | Whitening cosmetic | |
| JPH0987164A (en) | Skin preparation for external use | |
| KR101462692B1 (en) | Skin whitening cosmetics | |
| JP4842550B2 (en) | Tyrosinase activity inhibitor, melanin production inhibitor, and skin whitening external preparation | |
| JP2002370962A (en) | Bleaching preparation and cosmetic for preventing and improving aging of skin | |
| JP2006273822A (en) | Cosmetic containing clear liquor (shochu) lees | |
| JPH11222412A (en) | Skin preparation for external use | |
| KR20100061978A (en) | Skin whitening agent | |
| JPH04273808A (en) | Beautifying and whitening skin medicine for external use | |
| KR102160306B1 (en) | skin whitening agent | |
| JPH03200706A (en) | Dermal external agent | |
| KR101786606B1 (en) | cosmetics containing tetrandrine | |
| JPH11335256A (en) | Skin cosmetic | |
| JP2003321463A (en) | Skin care preparation |